[go: up one dir, main page]

CO2017013235A2 - Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral ox40 - Google Patents

Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral ox40

Info

Publication number
CO2017013235A2
CO2017013235A2 CONC2017/0013235A CO2017013235A CO2017013235A2 CO 2017013235 A2 CO2017013235 A2 CO 2017013235A2 CO 2017013235 A CO2017013235 A CO 2017013235A CO 2017013235 A2 CO2017013235 A2 CO 2017013235A2
Authority
CO
Colombia
Prior art keywords
antibodies against
necrosis factor
tumor necrosis
factor receptor
against tumor
Prior art date
Application number
CONC2017/0013235A
Other languages
English (en)
Inventor
Nils Lonberg
Mark J Selby
Mohan Srinivasan
Michelle Minhua Han
Bryan C Barnhart
Karla A Henning
Ming Lei
Liang Schweizer
Zhehong Cai
Indrani Chakraborty
Marie-Michelle Navarro GARCIA
Thomas D Kempe
Alan J Korman
Alexander T Kozhich
Hadia LEMAR
Mark Maurer
Christina Maria Milburn
Michael Quigley
Maria Rodriguez
Xiang Shao
Brenda L Stevens
Kent Thudium
Susan Chien-Szu Wong
Jochem Gokemeijer
xi-tao Wang
Han Chang
Christine Huang
Maria Jure-Kunkel
Zheng Yang
Yan Feng
Patrick Guirnalda
Aaron P Yamniuk
Sandra V Hatcher
Arvind Rajpal
Praveen Aanur
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO2017013235A2 publication Critical patent/CO2017013235A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)

Abstract

Se proporcionan en la presente los anticuerpos, o porciones de fijación al antígeno de éstos, que se fijan a OX40. También se proporcionan usos de estas proteínas en aplicaciones terapéuticas, por ejemplo, en el tratamiento contra el cáncer. También se proporcionan las células que producen los anticuerpos, polinucleótidos que codifican la región variable de las cadenas pesada y/o ligera de los anticuerpos, y vectores que comprenden los polinucleótidos que codifican la región variable de las cadenas pesada y/o ligera de los anticuerpos.
CONC2017/0013235A 2015-05-29 2017-12-21 Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral ox40 CO2017013235A2 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562168377P 2015-05-29 2015-05-29
US201562239574P 2015-10-09 2015-10-09
US201562264691P 2015-12-08 2015-12-08
US201662327140P 2016-04-25 2016-04-25
US201662333556P 2016-05-09 2016-05-09
PCT/US2016/034470 WO2016196228A1 (en) 2015-05-29 2016-05-26 Antibodies against ox40 and uses thereof

Publications (1)

Publication Number Publication Date
CO2017013235A2 true CO2017013235A2 (es) 2018-03-20

Family

ID=56121193

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0013235A CO2017013235A2 (es) 2015-05-29 2017-12-21 Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral ox40

Country Status (31)

Country Link
US (5) US9644032B2 (es)
EP (1) EP3303396B1 (es)
JP (3) JP6797137B2 (es)
KR (1) KR20180010264A (es)
CN (1) CN108137687B (es)
AU (1) AU2016271111B2 (es)
BR (1) BR112017025191A2 (es)
CA (1) CA2987410A1 (es)
CO (1) CO2017013235A2 (es)
DK (1) DK3303396T5 (es)
EA (1) EA035412B1 (es)
ES (1) ES2936317T3 (es)
FI (1) FI3303396T3 (es)
HR (1) HRP20230060T1 (es)
HU (1) HUE061253T2 (es)
IL (1) IL255949B2 (es)
LT (1) LT3303396T (es)
MX (1) MX2017015041A (es)
MY (1) MY188049A (es)
PE (1) PE20180926A1 (es)
PH (1) PH12017502129A1 (es)
PL (1) PL3303396T3 (es)
PT (1) PT3303396T (es)
RS (1) RS63897B1 (es)
SG (1) SG10202008304TA (es)
SI (1) SI3303396T1 (es)
SM (1) SMT202300013T1 (es)
TN (2) TN2019000101A1 (es)
TW (1) TWI732760B (es)
UY (1) UY36687A (es)
WO (1) WO2016196228A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
ES2649155T3 (es) * 2010-08-23 2018-01-10 Board Of Regents, The University Of Texas System Anticuerpos anti-OX40 y procedimientos de uso de los mismos
BR112016022345A2 (pt) 2014-03-31 2017-10-10 Genentech Inc terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
US20160362489A1 (en) * 2015-04-28 2016-12-15 Bristol-Myers Squibb Company Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody
MA42043A (fr) 2015-05-07 2018-03-14 Agenus Inc Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
EA035412B1 (ru) 2015-05-29 2020-06-10 Бристол-Майерс Сквибб Компани Антитела к ox40 и их применение
JP6771551B2 (ja) 2015-10-15 2020-10-21 ディンフー バイオターゲット カンパニー リミテッド 抗ｏｘ４０抗体及びその応用
MX2018006477A (es) 2015-12-02 2018-09-03 Agenus Inc Anticuerpos y metodos de uso de estos.
CN108602892A (zh) * 2016-01-27 2018-09-28 百时美施贵宝公司 使用抗-pd-1抗体和另一种抗癌剂的组合治疗肺癌
IL310729A (en) 2016-04-15 2024-04-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
JP7011764B2 (ja) 2016-07-07 2022-01-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗体アジュバント複合体
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
EP4342912A3 (en) * 2016-09-23 2024-05-22 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
KR20190095941A (ko) * 2016-12-19 2019-08-16 그렌마크 파머수티칼스 에스. 아. 신규 tnfr 효능제 및 이의 용도
US20200095327A1 (en) * 2017-02-08 2020-03-26 Dragonfly Therapeutics, Inc. Antibody heavy chain variable domains targeting the nkg2d receptor
DK3579848T3 (da) 2017-02-08 2025-01-20 Dragonfly Therapeutics Inc Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
MY200609A (en) * 2017-03-14 2024-01-05 Five Prime Therapeutics Inc Antibodies binding to vista at acidic ph
CA3054068A1 (en) * 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
CA3053812A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
CN108623685B (zh) * 2017-03-25 2022-07-01 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
CN108623686A (zh) 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
JP2020522541A (ja) * 2017-06-09 2020-07-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌を治療するためのｉｃｏｓアゴニストおよびｏｘ４０アゴニストでの組み合わせ療法
US11603410B2 (en) * 2017-11-01 2023-03-14 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
CN112292397B (zh) 2017-11-24 2023-01-31 祐和医药科技(北京)有限公司 抗ox40抗体及其用途
CN111770936A (zh) 2018-01-12 2020-10-13 百时美施贵宝公司 抗il-8抗体和抗pd-1抗体联合治疗用于治疗癌症
US20200405806A1 (en) 2018-02-08 2020-12-31 Bristol-Myers Squibb Company Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
AU2019239747A1 (en) 2018-03-21 2020-10-08 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
WO2019183551A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
MX2020009863A (es) * 2018-03-23 2021-01-08 Lilly Co Eli Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-l1.
WO2019214624A1 (en) * 2018-05-11 2019-11-14 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing same, and use thereof
CN113164588A (zh) * 2018-05-16 2021-07-23 詹森生物科技公司 治疗癌症并增强t细胞重定向治疗剂的功效的方法
WO2019223733A1 (en) 2018-05-23 2019-11-28 Beigene, Ltd. Anti-ox40 antibodies and methods of use
CN112638948A (zh) 2018-07-11 2021-04-09 戊瑞治疗有限公司 在酸性pH下结合至VISTA的抗体
WO2020014583A1 (en) 2018-07-13 2020-01-16 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR20210069058A (ko) 2018-09-26 2021-06-10 지앙수 헨그루이 메디슨 컴퍼니 리미티드 항-ox40 항체, 이의 항원-결합 단편 및 약학적 용도
US12195545B2 (en) 2018-12-25 2025-01-14 Hanx Biopharmaceutics, Inc Anti-OX40 monoclonal antibody and application thereof
WO2020142626A1 (en) * 2019-01-04 2020-07-09 Gigagen, Inc. Anti-ox40 binding proteins and methods of use thereof
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
EP3977132A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CN110172090B (zh) * 2019-06-03 2020-04-03 中山标佳生物科技有限公司 Cd134单克隆抗体及其制备方法和癌症治疗中的应用
EP4061844A4 (en) * 2019-11-21 2023-12-06 Beigene (Beijing) Co., Ltd. Methods of cancer treatment with anti-ox40 antibody in combination with chemotherapeutic agents
CA3156931A1 (en) * 2019-11-21 2021-05-27 Beibei JIANG Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
EP4061846A4 (en) * 2019-11-21 2023-12-20 BeiGene, Ltd. METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH ANTI-TIGIT ANTIBODIES
EP4061845A4 (en) * 2019-11-21 2023-12-13 BeiGene, Ltd. METHOD FOR CANCER TREATMENT USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH ANTI-TIM3 ANTIBODIES
KR20220121822A (ko) * 2019-12-03 2022-09-01 상하이 지아오 통 유니버시티 스쿨 오브 메디슨 FcγRIIB 친화력이 강화된 항체 Fc 영역
BR112022011949A2 (pt) * 2019-12-17 2022-11-22 Amgen Inc Dupla de interleucina-2/agonista do receptor tnf para uso em terapia
CN113045654A (zh) * 2019-12-27 2021-06-29 南开大学 抗ox40抗体及其用途
CN113045655A (zh) * 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
EP4130039A4 (en) * 2020-03-23 2024-07-31 Bio-Thera Solutions, Ltd. DEVELOPMENT AND APPLICATION OF AN IMMUNE CELL ACTIVATOR
US12157771B2 (en) 2020-05-06 2024-12-03 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
WO2021231237A2 (en) * 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
CN111704671B (zh) * 2020-08-19 2020-11-24 广东赛尔生物科技有限公司 Ox40抗体及其在治疗癌症中的应用
CN114106173A (zh) * 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 抗ox40抗体、其药物组合物及应用
CN114106174A (zh) * 2020-08-27 2022-03-01 苏州景涞医疗科技有限公司 低毒性抗ox40抗体、其药物组合物及应用
CN116438199A (zh) 2020-08-31 2023-07-14 百时美施贵宝公司 细胞定位特征和免疫疗法
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
AU2021401052A1 (en) 2020-12-18 2023-06-22 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
EP4267172A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
ES3023507T3 (en) 2020-12-28 2025-06-02 Bristol Myers Squibb Co Antibody compositions and methods of use thereof
CN112957475B (zh) * 2021-02-04 2022-07-22 李文峰 一种预防和或治疗肿瘤的组合物及应用
JPWO2022209717A1 (es) 2021-03-30 2022-10-06
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
CN118488965A (zh) * 2021-12-17 2024-08-13 上海复宏汉霖生物技术股份有限公司 抗ox40抗体、多特异性抗体及其使用方法
WO2023152116A1 (en) 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
US20250206775A1 (en) 2022-03-18 2025-06-26 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023221936A1 (zh) 2022-05-17 2023-11-23 苏州创胜医药集团有限公司 双功能蛋白质及其制剂和用途
KR20250022071A (ko) 2022-06-02 2025-02-14 브리스톨-마이어스 스큅 컴퍼니 항체 조성물 및 이의 이용 방법
EP4583999A1 (en) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Methods of separating chelator
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Family Cites Families (238)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5620886A (en) 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
JPH08507549A (ja) 1993-12-27 1996-08-13 バクスター、インターナショナル、インコーポレイテッド 水溶性の非免疫原性ポリアミド架橋剤
US5759546A (en) 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO1997012862A1 (en) 1995-10-03 1997-04-10 The Scripps Research Institute Cbi analogs of cc-1065 and the duocarmycins
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6069233A (en) 1996-10-03 2000-05-30 Memorial Sloan-Kettering Cancer Center Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
EP1997893A1 (en) 1998-02-24 2008-12-03 Sisters of Providence in Oregon Compositions containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
US6312700B1 (en) * 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
ES2532910T3 (es) 1998-04-02 2015-04-01 Genentech, Inc. Variantes de anticuerpos y fragmentos de los mismos
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
SI1141028T1 (sl) 1998-12-23 2010-05-31 Pfizer Človeška monoklonska protitelesa proti CTLA
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP4118462B2 (ja) 1999-07-19 2008-07-16 株式会社リコー 携帯電子機器
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
HUP0202882A2 (en) 1999-08-23 2002-12-28 Dana Farber Cancer Inst Inc Novel b7-4 molecules and uses therefor
DE60033530T2 (de) 1999-08-24 2007-10-31 Medarex Inc. Humane antikörper gegen ctla-4 und deren verwendungen
NZ517215A (en) 1999-08-25 2004-01-30 Immunex Corp Compositions and methods for improved cell culture
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US6774226B1 (en) 1999-11-30 2004-08-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
IL151865A0 (en) 2000-03-31 2003-04-10 Genentech Inc Compositions and methods for detecting and quantifying gene expression
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US6794501B2 (en) 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
WO2002092780A2 (en) 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
ITMI20011465A1 (it) 2001-07-10 2003-01-10 Novuspharma Spa Gene ad attivita' oncosoppressiva
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP1525223B1 (en) 2002-06-13 2007-11-21 Crucell Holland B.V. Ox40 (=cd134) receptor agonists and therapeutic use
WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
EP1562972B1 (en) 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
EP2364716A3 (en) 2002-11-08 2012-01-11 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
CA2737127C (en) 2003-05-14 2016-07-26 Immunogen, Inc. Maytansinoid-antibody conjugate compositions
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ATE535249T1 (de) 2003-06-13 2011-12-15 Univ Pennsylvania Vakzine, immuntherapeutika und verfahren zu ihrer verwendung
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US7396914B2 (en) * 2003-08-04 2008-07-08 University Of Massachusetts SARS nucleic acids, proteins, antibodies, and uses thereof
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
EP1706424B1 (en) 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
US20050288491A1 (en) 2004-02-17 2005-12-29 Wilson David S Super-humanized antibodies against respiratory syncytial virus
AU2005227326B2 (en) 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
US7778814B2 (en) 2004-03-30 2010-08-17 Siemens Aktiengesellschaft Method and device for simulating an automation system
EP1776384B1 (en) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variant fc regions
WO2006029459A1 (en) * 2004-09-13 2006-03-23 Evogenix, Inc Antibodies specific for hepatocellular carcinoma and other carcinomas and uses thereof
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
MX2007006117A (es) 2004-11-23 2007-07-13 Pip Co Ltd Caja de llave de servicio de agua empotrada en la pared.
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
NZ586780A (en) * 2005-03-23 2012-02-24 Genmab As Antibodies against CD38 for treatment of multiple myeloma
CN103059138B (zh) 2005-05-09 2015-10-28 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
EA026785B1 (ru) 2005-05-10 2017-05-31 Инсайт Холдингс Корпорейшн Модуляторы индоламин 2,3-диоксигеназы и способы их применения
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
ME02260B (me) 2005-07-01 2016-02-29 Medarex Inc Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
WO2007038868A2 (en) 2005-10-03 2007-04-12 The University Of British Columbia Novel enediyne compound and uses thereof
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
CN101360761B (zh) * 2005-12-08 2012-09-12 米德列斯公司 抗蛋白质酪氨酸激酶7（ptk7）的人单克隆抗体及其用途
JP5294874B2 (ja) 2005-12-20 2013-09-18 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロ環
WO2007084559A2 (en) 2006-01-13 2007-07-26 Board Of Regents, The University Of Texas System Methods to treat disease states by influencing the signaling of ox40-receptors and high throughput screening methods for identifying substances therefor
AR062448A1 (es) 2006-05-25 2008-11-12 Endocyte Inc Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
PE20080316A1 (es) 2006-05-25 2008-04-10 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
WO2007149880A2 (en) 2006-06-21 2007-12-27 Genentech, Inc. Crystal structure of ox40l and ox40l complexed with ox40 receptor
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
WO2008106116A2 (en) 2007-02-27 2008-09-04 Genentech, Inc. Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
CN101674847A (zh) 2007-05-02 2010-03-17 弗·哈夫曼-拉罗切有限公司 稳定蛋白质的方法
KR101380732B1 (ko) 2007-05-30 2014-04-10 포항공과대학교 산학협력단 면역글로불린 융합 단백질
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
DE102007036200A1 (de) 2007-08-02 2009-02-05 Knorr-Bremse Systeme für Nutzfahrzeuge GmbH Induktiver Weg- oder Drehwinkelsensor mit zwischen zwei Spulen angeordnetem Abschirmblech
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009059278A1 (en) 2007-11-02 2009-05-07 Centocor, Inc. Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses
EP2227233B1 (en) 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
EP2229410A4 (en) 2007-12-05 2012-07-04 Massachusetts Inst Technology AGLYCOSYLATED IMMUNOGLOBULIN MUTANES
DK2242771T3 (da) 2007-12-14 2013-08-26 Pfizer Bindingsmolekyler til den humane ox40-receptor
EP2235059B1 (en) 2007-12-26 2015-02-18 Xencor, Inc. Fc variants with altered binding to fcrn
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
AU2009233708B2 (en) 2008-04-09 2015-06-04 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
EP2282773B2 (en) 2008-05-02 2025-03-05 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20100189727A1 (en) 2008-12-08 2010-07-29 Tegopharm Corporation Masking Ligands For Reversible Inhibition Of Multivalent Compounds
MY188826A (en) 2008-12-09 2022-01-06 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
CN116925238A (zh) 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
CA2751477C (en) 2009-02-17 2019-08-27 Ucb Pharma S.A. Antibody molecules having specificity for human ox40
US20110007023A1 (en) 2009-07-09 2011-01-13 Sony Ericsson Mobile Communications Ab Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
SG10201501784YA (en) 2009-12-07 2015-05-28 Univ Leland Stanford Junior Methods for enhancing anti-tumor antibody therapy
ES2557454T3 (es) 2009-12-10 2016-01-26 F. Hoffmann-La Roche Ag Anticuerpos que se unen al dominio extracelular 4 de CSF1R humana y su utilización
EP2509409B1 (en) 2009-12-10 2016-07-27 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
RU2724663C2 (ru) 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
PL3053932T3 (pl) 2010-02-19 2021-03-08 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
MA34062B1 (fr) 2010-03-04 2013-03-05 Macrogenics Inc Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées
EP2542587A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
CN102971329B (zh) 2010-04-15 2016-06-29 麦迪穆有限责任公司 用于治疗增殖性疾病的吡咯并苯并二氮杂卓
KR101772354B1 (ko) 2010-04-15 2017-08-28 시애틀 지네틱스, 인크. 표적화된 피롤로벤조디아제핀 접합체
TW202112827A (zh) 2010-05-04 2021-04-01 美商戊瑞治療有限公司 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類
PT2905338T (pt) 2010-06-22 2017-11-10 Regeneron Pharma Ratinhos transgénicos com um locus de imunoglobulina lambda endógeno modificado
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
ES2649155T3 (es) 2010-08-23 2018-01-10 Board Of Regents, The University Of Texas System Anticuerpos anti-OX40 y procedimientos de uso de los mismos
KR101527297B1 (ko) 2010-09-09 2015-06-26 화이자 인코포레이티드 4-1ｂｂ 결합 분자
CA2824278C (en) 2010-12-20 2022-09-20 The Rockefeller University Modulating agonistic tnfr antibodies
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
DK2697257T3 (en) 2011-04-13 2017-01-30 Bristol Myers Squibb Co FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS
NO2694640T3 (es) 2011-04-15 2018-03-17
SMT201800294T1 (it) 2011-04-20 2018-07-17 Medimmune Llc Anticorpi e altre molecole che legano b7-h1 e pd-1
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
JP5708369B2 (ja) 2011-08-24 2015-04-30 コベルコ建機株式会社 作業機械
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
CA2849039C (en) 2011-09-20 2018-09-18 Spirogen Sarl Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates
US20130149300A1 (en) 2011-09-27 2013-06-13 Icon Genetics Gmbh MONOCLONAL ANTIBODIES WITH ALTERED AFFINITIES FOR HUMAN FCyRI, FCyRIIIa, AND C1q PROTEINS
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
EP2791174B1 (en) 2011-12-15 2018-02-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
EP3485909A1 (en) 2011-12-19 2019-05-22 The Rockefeller University Non-sialylated anti-inflammatory polypeptides
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
EP2812022B1 (en) 2012-02-06 2019-06-26 Providence Health & Services - Oregon Method of monitoring cancer treatment using ox40 agonists
MX350539B (es) 2012-02-13 2017-09-08 Bristol Myers Squibb Co Compuestos de enediino, conjugados de los mismos y sus usos y metodos.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
HK1208233A1 (en) 2012-05-11 2016-02-26 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CA2882804A1 (en) 2012-08-31 2014-03-06 Brian Wong Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
HUE043482T2 (hu) 2012-09-13 2019-08-28 Bristol Myers Squibb Co Miosztatint megkötõ fibronektin alapú váz domén proteinek
WO2014089113A1 (en) 2012-12-03 2014-06-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
MX356698B (es) 2013-02-14 2018-06-11 Bristol Myers Squibb Co Compuestos de tubulisina, metodos para obtenerlos y uso.
SMT201800503T1 (it) * 2013-03-18 2018-11-09 Janssen Pharmaceuticals Inc Anticorpi anti-cd (ox40) umanizzati e loro usi
HRP20201404T1 (hr) 2013-07-16 2020-11-27 F. Hoffmann - La Roche Ag Postupci liječenja raka primjenom pd-1 osno vezujućeg antagonista i inhibitora tigita
AU2014364593A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
EP3083687A2 (en) 2013-12-17 2016-10-26 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015131176A1 (en) 2014-02-28 2015-09-03 Podack Eckhard R Compositions, methods, and kits for treatment of cancer
BR112016022345A2 (pt) 2014-03-31 2017-10-10 Genentech Inc terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
LT3126394T (lt) 2014-03-31 2020-01-27 F. Hoffmann-La Roche Ag Antikūnai prieš ox40 ir jų naudojimo būdai
TWI691335B (zh) 2014-07-09 2020-04-21 英屬開曼群島商博笛生物科技有限公司 用於治療腫瘤的抗pd-l1組合
CN112546231A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
BR112017006664A2 (pt) 2014-10-03 2017-12-26 Novartis Ag terapias de combinação
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
US11285194B2 (en) 2014-10-24 2022-03-29 Calidi Biotherapeutics, Inc. Combination immunotherapy approach for treatment of cancer
RU2017119231A (ru) 2014-11-03 2018-12-06 Дженентек, Инк. Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40
US11236139B2 (en) 2014-11-05 2022-02-01 The Regents Of The University Of California Combination immunotherapy
KR20170072343A (ko) 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
EA035412B1 (ru) 2015-05-29 2020-06-10 Бристол-Майерс Сквибб Компани Антитела к ox40 и их применение

Also Published As

Publication number Publication date
JP2018520657A (ja) 2018-08-02
US20200399385A1 (en) 2020-12-24
MY188049A (en) 2021-11-12
CN108137687B (zh) 2021-10-29
LT3303396T (lt) 2023-01-10
TW201708255A (zh) 2017-03-01
PL3303396T3 (pl) 2023-03-06
FI3303396T3 (fi) 2023-02-22
US20180237534A1 (en) 2018-08-23
WO2016196228A1 (en) 2016-12-08
SMT202300013T1 (it) 2023-03-17
AU2016271111B2 (en) 2022-04-28
TWI732760B (zh) 2021-07-11
TN2017000488A1 (en) 2019-04-12
BR112017025191A2 (pt) 2018-07-31
JP6797137B2 (ja) 2020-12-09
CA2987410A1 (en) 2016-12-08
EP3303396A1 (en) 2018-04-11
RS63897B1 (sr) 2023-02-28
HRP20230060T1 (hr) 2023-03-17
US20230272100A1 (en) 2023-08-31
KR20180010264A (ko) 2018-01-30
IL255949A (en) 2018-01-31
TN2019000101A1 (en) 2020-07-15
US9644032B2 (en) 2017-05-09
SG10202008304TA (en) 2020-10-29
JP7119051B2 (ja) 2022-08-16
HK1246308A1 (en) 2018-09-07
DK3303396T5 (da) 2024-10-07
ES2936317T3 (es) 2023-03-16
EP3303396B1 (en) 2022-11-23
EA035412B1 (ru) 2020-06-10
JP2022169570A (ja) 2022-11-09
PE20180926A1 (es) 2018-06-08
US20170306035A1 (en) 2017-10-26
IL255949B2 (en) 2023-06-01
US10683357B2 (en) 2020-06-16
SI3303396T1 (sl) 2023-01-31
PT3303396T (pt) 2023-01-30
PH12017502129A1 (en) 2018-04-02
CN108137687A (zh) 2018-06-08
MX2017015041A (es) 2018-02-26
US20160347849A1 (en) 2016-12-01
EA201792572A1 (ru) 2018-05-31
DK3303396T3 (da) 2023-02-27
JP2021058186A (ja) 2021-04-15
US11466092B2 (en) 2022-10-11
HUE061253T2 (hu) 2023-06-28
UY36687A (es) 2016-11-30
AU2016271111A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
CO2017013235A2 (es) Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral ox40
MX374171B (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos.
CL2018003153A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer.
EA201891121A1 (ru) Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
CO2019000372A2 (es) Anticuerpos contra proteína 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
CL2018001369A1 (es) Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia de cáncer (divisional solicitud 201700836)
BR112016030740A2 (pt) diacorpos heterodiméricos biespecíficos e seus usos
SV2018005634A (es) Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y usos de estos
CO2017008047A2 (es) Polipéptidos que se unen a proteínas de la superfamilia del receptor del factor de necrosis tumoral
MX2017007744A (es) Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmumorreceptor (tigit).
UY35399A (es) Conjugados de fármacos con anticuerpos
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
CL2017003020A1 (es) Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos
EA202090533A2 (ru) Антитела к ox40 и их применение
AR100744A1 (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
UY36344A (es) Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer